C
rohn's disease (CD) is characterized by the excessive release of proinflammatory cytokines that drive the pathogenesis and progression of the disease in the gastrointestinal (GI) tract. 1 These cytokines interact to develop an immense and complicated network that induces, propagates, and perpetuates mucosal inflammatory reactions, 2,3 disrupts the intestinal epithelial stem cells, which suppresses their proliferation and differentiation 4 and eventually precludes disease remission and mucosal healing, and leads to serious complications that include abscesses, fistulas, and stenoses. Many cytokines, including interferon-g, tumor necrosis factor a (TNF-a), and interleukins (ILs) 6, 12, 15, 16, 17, 18, 21 , and 23 contribute to the immune responses associated with CD. 5, 6 IL-9 is an important inflammatory cytokine that is produced mainly by T-helper (Th) 9 cells, 7 type 2 innate lymphoid cells (ILC2s), 8, 9 and mast cells. 10 It specifically binds to the IL-9 receptor (IL-9R), which is expressed on both hematopoietic cells and nonhematopoietic cells, for example, the intestinal epithelial cells, and initiates the IL-9-IL-9R pathway that phosphorylates the Janus kinases 1/3 and then activates downstream transcription factors, in particular, members of the signal transducer and activator of transcription protein family, namely, 1, 3, and 5. 11, 12 Intestinal IL-9 levels increase significantly in patients with severe ulcerative colitis. 7, 13 Furthermore, IL-9 regulates the expression of tight junction proteins on the epithelial cells, and high levels of IL-9 in the tissues are involved in the damage of the intestinal barrier function, which is detrimental to mucosal healing. 7, 13 Notably, IL-9 has a similar effect on the intestinal epithelial cells in an experimental murine model of CD in which colitis is induced by 2,4,6-trinitrobenzenesulfonic acid. 14 Moreover, IL-9 facilitates the IL-4-induced production of immunoglobulin (Ig) G and IgE in both murine and human B cells in vitro, and it enhances the expansion of the B-1 lymphocyte subset. 15, 16 Hence, it is reasonable to speculate that IL-9 may be a marker of disease severity, the clinical efficacy of infliximab (IFX) therapy, and the formation of antibodies to IFX (ATI) in patients with CD. Therefore, this study aimed to explore the correlations between the serum IL-9 levels and disease severity, the clinical efficacy of IFX, and ATI formation in CD.
MATERIALS AND METHODS

Patients
Between January 2013 and December 2015, 100 patients who had active CD and were hospitalized at the First Affiliated Hospital, Sun Yat-sen University to obtain a diagnosis, to undergo an elective ileocolonoscopy or for a CD exacerbation were enrolled to participate in the study. The Crohn's Disease Activity Index (CDAI) and the Crohn's Disease Endoscopic Index of Severity (CDEIS) scores were calculated for each patient. Eligible patients had a CDAI score of .150, endoscopically confirmed mucosal ulceration, and serum samples collected at baseline before any interventions. The exclusion criteria were symptomatic strictures, abdominal abscesses, fistulas, stomas, short bowel syndrome, isolated upper GI tract involvement, pregnancy or lactation, a history of malignancy, ongoing infections, concurrent autoimmune diseases, including asthma, and the absence of serum samples taken at baseline. Simultaneously, 50 age-and sexmatched healthy individuals who did not have histories of autoimmune diseases and underwent routine physical examinations at the same hospital were included as controls. Demographic data were collected from all the subjects.
For the patients with CD, data describing the duration of the disease, and its severity, location, and behavior, the presence of perianal lesions and extraintestinal manifestations, bowel surgery, current therapy, and the results from blood tests to determine the hemoglobin level, platelet count, albumin level, and the Creactive protein level were extracted from the patients' electronic medical records. The Montreal classification was applied to categorize the activity, location, and behavior of the disease. 17 Using the CDAI score, disease activity was categorized into mild (CDAI score: 150-220), moderate (CDAI: score 220-450), or severe (CDAI score: .450) disease. The location of the disease was categorized as L1, which represented terminal ileum involvement, L2, which represented colon involvement, or L3, which represented ileocolon involvement, irrespective of upper GI tract involvement. Disease behavior was categorized into 3 phenotypes, namely, nonstricturing nonpenetrating (B1), stricturing (B2), or penetrating (B3).
Within the group of 100 patients with active CD was a third cohort that comprised those who had started IFX therapy. IFX is a chimeric monoclonal antibody against TNF-a, which has been used to treat CD since the 1990s. 18 It was administered at 5 mg/kg on weeks 0, 2, and 6, and every 8 weeks thereafter at our hospital. Serum samples were collected from these patients just before every infusion. Ileocolonoscopy was performed on weeks 14 and 30. Patients who had received at least 6 infusions of IFX, had complete follow-up data until week 30, had serum samples removed on weeks 14 and 30, and had undergone an endoscopy examination on week 30 were included in the third cohort for further analysis.
METHODS
The patients' serum IL-9 levels were determined using an enzyme-linked immunosorbent assay (ELISA) kit (Catalog No: E-EL-H0180c; Elabscience Biotechnology Co., Ltd, Wuhan City, Hubei, China). Briefly, 100 mL of the standard solutions containing known concentrations of IL-9 from 15.625 to 1000 pg/mL, the blank solution, and the patients' sera were added to wells that were precoated with an antibody specific to human IL-9, and they were incubated for 90 minutes at 378C. After washing, a biotinylated antibody (100 mL) that was specific to human IL-9 was added to each well, and the wells were incubated for 1 hour at 378C. After washing the wells 3 times, an avidin-horseradish peroxidase conjugate solution (100 mL) was added to each well, and the wells were incubated for 30 minutes at 378C. After washing, a substrate solution (90 mL) was added to each well, and the wells were incubated for approximately 15 minutes at 378C. Finally, a stop solution (50 mL) was added to each well. The results were read at a wavelength of 450 nm using an ELISA reader (Infinite F50; Tecan Group Ltd., Zürich, Switzerland).
The serum TNF-a levels were measured in a similar manner using a different ELISA kit (Catalog No: EH009; ExCell Bio, Inc., Shanghai, China). The IFX and ATI levels were detected using previously described ELISA protocols. 19 
Outcomes
Clinical remission was defined as a CDAI score ,150. 17 A clinical response was defined as a change in the CDAI score .2100. 17 Mucosal healing was defined as the complete absence of ulceration based on an endoscopic examination. 20 
Statistical Analyses
IBM SPSS software, version 20 (IBM Corporation, Armonk, NY), was used to analyze the data. OriginPro software, version 9.1 (OriginLab Corporation, Northampton, MA), and GraphPad Prism software, version 6 (GraphPad Software, Inc., La Jolla, CA), were used to plot the graphs. The discrete data are expressed as numbers and percentages, and the continuous data are expressed as the means and the SDs or as the medians and the interquartile ranges (IQRs). The correlation analyses were performed using Spearman's rank correlation coefficient, and the groups were compared using the chi-square test, Student's t test, or a nonparametric test, as appropriate. Receiver operating characteristic curves were plotted to enable the assessment of the discriminatory abilities of the IL-9 levels in relation to the clinical outcomes at week 30, and the optimal cutoff points and the areas under the curves with the 95% confidence intervals (CIs) were calculated. The alpha error for statistical significance was set at a 2-tailed value of 0.05.
Ethical Considerations
The hospital's institutional review board approved the protocol, and every participant provided written informed consent.
RESULTS
Elevated Serum IL-9 Levels in Patients with Active CD Table 1 summarizes the demographic and clinical data from the patients with active CD (n ¼ 100) and the healthy control individuals (n ¼ 50). IL-9 levels that were above the 95th percentile in the control group were defined as being higher than the upper normal level, and 88% of the patients with CD had elevated IL-9 levels and higher CDAI and CDEIS scores compared with those with normal IL-9 levels (P , 0.05) (see Supplementary Serum IL-9 Levels Are Closely Related to CD Severity
The patients with CD were categorized based on their CDAI scores into those with mild disease (37/100) and those with moderate-to-severe disease (63/100). The patients with mild CD were usually hospitalized for workups for a CD diagnosis or for elective ileocolonoscopy. The patients with moderate-to-severe CD had a median IL-9 level of 29.1 (IQR: 21.5-60.0) pg/mL, which was significantly higher than that in the patients with mild CD (12.9 [IQR: 11.6-15.9] pg/mL) (P , 0.001) (Fig. 1 ). There were no differences in the IL-9 levels in relation to sex (P ¼ 0.665), the disease site (P ¼ 0.465), the behavior of the disease (P ¼ 0.950), the presence of perianal lesions (P ¼ 0.134), or the presence of extraintestinal manifestations (P ¼ 0.907).
The serum TNF-a level was significantly higher in the patients with moderate-to-severe CD (21.2 [IQR: 8.3-37.1] pg/mL) compared with that in the patients with mild CD (10.7 [IQR: 1.85-17.8] pg/mL) (P ¼ 0.002) (Fig. 1) . The serum TNF-a levels were strongly correlated with the serum IL-9 levels (r ¼ 0.467; P , 0.001) and the C-reactive protein levels (r ¼ 0.463; P , 0.001) (see Supplementary Fig. 1 , Supplemental Digital Content 2, http://links.lww.com/IBD/B536). Patients with isolated upper GI disease were excluded. B1, nonstricturing nonpenetrating; B2, structuring; B3, penetrating; CD, Crohn's disease; L1, terminal ileum; L2, colon; L3, ileocolon. FIGURE 1. The serum interleukin (IL)-9 level was upregulated in the patients with active CD. The IL-9 level was higher in the patients with active CD (n ¼ 100) compared with that in the 50 healthy control individuals. The IL-9 and TNF-a levels in the patients with moderateto-severe CD were considerably higher than those in the patients with mild CD. ***P , 0.001.
Correlations between the serum IL-9 level and the C-reactive protein level, the CDAI score, the CDEIS score, the platelet count, the albumin level, and the hemoglobin concentration were explored in the patients with CD. The IL-9 level was positively correlated with the C-reactive protein level (r ¼ 0.496), the CDAI score (r ¼ 0.644), the CDEIS score (r ¼ 0.395), and the platelet count (r ¼ 0.227) (all P , 0.05), and it was negatively correlated with the albumin level (r ¼ 20.353; P , 0.05) and the hemoglobin concentration (r ¼ 20.308; P , 0.05) (Fig. 2) .
IL-9 Levels in Patients with CD Who Received IFX
The data from a subgroup of 50 patients with CD who started IFX therapy and received at least 6 IFX infusions were analyzed further. Data describing their IL-9 levels were available at weeks 0, 14, and 30, and the patients had undergone final endoscopic examinations at week 30. Table 2 summarizes the patients' baseline characteristics. The median age of these patients was 19.0 (IQR: 15.0-23.3) years, the median disease duration was 1.0 (IQR: 0.8-3.3) years, and 70.0% of the patients were male. The median C-reactive protein levels were 14.3 (IQR: 4.6-32.5) mg/L, 2.6 (IQR: 0.6-9.0) mg/L, and 3.5 (IQR: 0.6-11.9) mg/L at weeks 0, 14, and 30, respectively, and the median IL-9 levels were 25.3 (IQR: 16.0-43.9) pg/mL, 11.9 (IQR: 8.3-25.2) pg/mL, and 9.6 (IQR: 6.6-19.4) pg/mL at weeks 0, 14, and 30, respectively, (Fig. 3A, B) . Eighteen of the 50 patients had not responded to IFX therapy by week 30, and their serum IL-9 levels did not show any significant changes at weeks 0, 14, and 30 (P ¼ 0.748) (Fig. 3C) . During IFX therapy, the nonresponsive patients had higher median IL-9 levels compared with those in the responsive patients at week 14 (18. At week 14, 41 of the 50 patients (82.0%) underwent ileocolonoscopy. The serum IL-9 levels declined significantly after IFX therapy in the patients who had achieved clinical remission compared with those who did not achieve clinical remission. In addition, the trough IFX and ATI levels were measured, and the IFX levels were markedly higher in the subjects who attained clinical efficacy compared with those who did not attain clinical efficacy, whereas there were no differences with respect to the ATI levels (Table 3) .
At week 30, 40 of the 50 patients with CD (80.0%) had achieved clinical remission. Compared with the patients who did not achieve clinical remission, those who were in clinical remission had lower IL-9 and C-reactive protein levels, platelet counts, and CDEIS scores and higher albumin and hemoglobin levels (Table 4) . Twenty-three patients (46.0%) showed mucosal healing, and these patients had significantly lower IL-9 and Creactive protein levels, platelet counts, and CDAI scores and their albumin and hemoglobin levels had increased dramatically ( Table 4) .
The receiver operating characteristic curve analysis showed that the optimal threshold values for the IL-9 levels at week 30 were 21.5 pg/mL for clinical remission and 18.1 pg/mL for mucosal healing (Fig. 4 and Table 5 ). Moreover, the IL-9 levels at week 14 could predict the clinical efficacy of IFX at week 30, with optimal threshold values of 17.4 pg/mL for clinical remission and 15.5 pg/mL for mucosal healing (both P , 0.05) (Fig. 4 and Table 5 ).
DISCUSSION
This study's results demonstrated that the serum IL-9 level was upregulated in patients with active CD and that it increased with disease severity. In addition, IL-9 showed strong correlations with the CD severity markers, namely, C-reactive protein, TNF-a, the CDEIS score, and the CDAI score. Furthermore, the IL-9 level declined markedly after IFX therapy, and it was predictive of the drug's clinical efficacy at week 30.
The findings from studies of mouse models of intestinal anaphylaxis have demonstrated that IL-9 promotes intestinal mastocytosis and that it increases permeability and intravascular leakage. 21 IL-9 promotes IL-5 and IL-13 production, eosinophilia, basophilia, and mastocytosis during GI worm expulsion. 22 Moreover, IL-9 is associated with the pathogenesis of ulcerative colitis because it acts on the polymorphonuclear leukocytes (PMNs) and epithelial cells. Specifically, IL-9 induces PMNs to produce IL-8 in a dose-dependent manner, and IL-8, in turn, prolongs PMN survival. 13 Long-lived PMNs perpetuate gut inflammation and directly damage epithelial cells. The findings from another study showed that IL-9 leads to an imbalance of epithelial protein expression. 7 Furthermore, IL-9 inhibits epithelial proliferation by controlling several gene-encoding products. A mouse model FIGURE 3. The serum C-reactive protein and interleukin (IL)-9 levels in 50 patients with CD who were administered at least 6 IFX infusions at weeks 0, 14, and 30. A, Serum C-reactive protein levels. B, Serum IL-9 levels. C, The serum IL-9 levels in 18 nonresponsive patients with CD who were administered at least 6 IFX infusions at weeks 0, 14, and 30. ***P , 0.001. ns, not significant. of CD in which T cell-mediated colitis is induced by 2,4,6-trinitrobenzenesulfonic acid showed similar results, 14 and these effects eventually impair the intestinal barrier function and hamper mucosal healing. Although the findings from 2 of the aforementioned studies did not show any differences between patients with active and inactive CD or between patients with active CD and control individuals in relation to the expression of IL-9 messenger RNA in the tissues, 7,13 the current study's findings demonstrated a significant increase in the serum IL-9 level in the patients with active CD and strong positive correlations between the IL-9 level and disease severity. Defendenti et al 23 also demonstrated that the serum IL-9 level correlated significantly with the severity of CD, which concurs with our findings. Our focus on the systemic IL-9 protein levels rather than on the local expression of IL-9 messenger RNA in the tissues may explain these conflicting results. It is possible that there may be some posttranscriptional modifications that cause discrepancies between the IL-9 messenger RNA level and the protein level. In addition to Th9 cells, mast cells, and ILC2s, Th17 cells, which are characterized by the production of IL-17 and are involved in the pathogenesis of CD, are another source of IL-9. However, an antibody that targeted IL-17A did not show positive results in patients with CD. 5 These observations imply that other cytokines, including IL-9, might be important in the pathogenesis of CD. Furthermore, we enrolled patients with more active CD who had mucosal ulceration that was detected by endoscopy, and this may have also contributed to the differences between the results from our study and those from other studies.
Intriguingly, IL-9 exerts some of its functions through epithelial cells, PMNs, and eosinophils. The roles of these cells in CD are increasingly being studied. Epithelial barrier defects comprise increases in intestinal permeability, decreases in epithelial integrity, and abnormalities in the composition of the mucus, and they cause gut inflammation in CD. 2, 24 Disturbances in PMN functionality, basophilia, and eosinophilia have been reported in CD, whereas the role of the mast cell is considered less important. [25] [26] [27] [28] These findings, taken together with those from this study, suggest that IL-9 may act on a variety of cells, including Th17 cells, epithelial cells, eosinophils, and antigen- presenting cells, to exert its pleiotropic effects, 12, 29 and that it may, therefore, be involved in the pathogenesis of CD. Hence, IL-9 could be a potential therapeutic target in CD. Although IFX is superior at inducing and sustaining corticosteroid-free clinical remission and at healing the mucosa in patients with active CD compared with conventional immunosuppressive drugs, 20, 30 primary nonresponses occur in 20% to 40% and secondary losses of response occur in 23% to 46% of patients with inflammatory bowel disease. 31 Given that IFX therapy also places a heavy burden on society, finding indicators that can predict the efficacy of IFX and guide clinical interventions would be cost effective for patients and society.
A high baseline C-reactive protein level predicts the response of a patient with CD to IFX, and its early normalization indicates a sustained long-term response. 32 Moreover, an increase in the C-reactive protein level predicts the decline in the trough IFX concentration that precedes the loss of a response. 33 Our study's findings showed that the IL-9 levels could distinguish between IFX responders and nonresponders and that they showed strong correlations with the C-reactive protein levels.
A detectable trough IFX level is associated with clinical remission, a low C-reactive protein level, and endoscopic improvement, 34 whereas the presence of ATI increases the risk of infusion reactions, lowers the IFX levels, and reduces the response duration. 35 Notably, therapeutic drug monitoring of the IFX and ATI levels could inform decision-making about clinical interventions for patients who experience a loss of response. 36 In our study, high serum trough IFX concentrations were associated with clinical efficacy in the patients with CD. Unfortunately, a relationship between the IL-9 level and ATI formation is yet to be determined. In addition to C-reactive protein, IFX, ATI, and many other biomarkers, including matrix metalloproteinase-9 and osteoprotegerin, have been investigated in relation to IFX therapy. 37, 38 Our study's findings clearly showed that the IL-9 level declined in patients with CD who had favorable therapeutic effects after 30 weeks of IFX therapy, and the area under the curve values for the IL-9 levels that predicted clinical remission and mucosal healing ranged from 0.746 to 0.781. Interestingly, the cutoff values for IL-9 were incrementally lower when we aimed to predict clinical remission and mucosal healing, which may reflect the increasing level of inflammatory suppression required to achieve these outcomes in clinical practice.
More importantly, the IL-9 level at week 14 could predict the therapeutic effects of IFX at week 30. The area under the curve values for the IL-9 levels at week 14 that predicted clinical remission and mucosal healing were 0.803 and 0.752, respectively. Hence, the IL-9 levels could be used to monitor the efficacy of IFX in patients to enhance the predictive strength of C-reactive protein.
In conclusion, our study's findings provide preliminary evidence that the serum IL-9 levels might play a role in CD exacerbations. Our findings also suggest that IL-9 may be another promising noninvasive biomarker that could be used to monitor disease activity and IFX efficacy in patients with CD. However, the precise manner in which IL-9 contributes to the pathogenesis of CD warrants further investigation.
